<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61741">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302157</url>
  </required_header>
  <id_info>
    <org_study_id>AST-OPC1-01</org_study_id>
    <nct_id>NCT02302157</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of AST-OPC1 in Spinal Cord Injury</brief_title>
  <official_title>A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asterias Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asterias Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of 3 sequential escalating doses of
      AST-OPC1 administered at a single time-point between 14 and 30 days post injury,
      inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events within 1 year (365 days) that are related to AST-OPC1 injection</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological function as measured by upper extremity motor scores and motor level on International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examinations at 30, 60, 90, 180, and 365 days after injection of AST-OPC1</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cervical Spinal Cord Injury</condition>
  <condition>Spine Injury</condition>
  <condition>Spinal Cord Trauma</condition>
  <arm_group>
    <arm_group_label>AST-OPC1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AST-OPC1</intervention_name>
    <description>One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent</description>
    <arm_group_label>AST-OPC1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3

          -  Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5

          -  Last fully preserved single neurological level (SNL) from C-5 to C-7

          -  From 18 through 69 years of age at time of injury

          -  Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI)
             scan, with sufficient visualization of the spinal cord injury epicenter and lesion
             margins to enable post-injection safety monitoring

          -  Informed consent for this protocol and the companion long term follow-up protocol
             must be provided and documented (i.e., signed informed consent forms) no later than
             25 days following injury

          -  Able to participate in an elective surgical procedure to inject AST-OPC1 14-30 days
             following SCI

        Major Exclusion Criteria:

          -  SCI due to penetrating trauma

          -  Traumatic anatomical transection or laceration of the spinal cord based on prior
             surgery or MRI

          -  Any concomitant injury that interferes with the performance, interpretation or
             validity of neurological examinations

          -  Inability to communicate effectively with neurological examiner such that the
             validity of patient data could be compromised

          -  Significant organ damage or systemic disease that would create an unacceptable risk
             for surgery or immunosuppression

          -  History of any malignancy (except non-melanoma skin cancers)

          -  Pregnant or nursing women

          -  Body mass index (BMI) &gt; 35 or weight &gt; 300 lbs.

          -  Active participation in another experimental procedure/intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward D Wirth III, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Asterias Biotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rancho Los Amigos/USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheetal Desai</last_name>
      <phone>562-401-7020</phone>
      <email>sheetald@ranchoresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Oviedo</last_name>
      <phone>(323) 865-9873</phone>
      <email>sandra.oviedo@health.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Liu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University/Santa Clara Valley Medical Center</name>
      <address>
        <city>Stanford/San Jose</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Ehsanian</last_name>
      <phone>408-885-2153</phone>
      <email>Reza.Ehsanian@hhs.sccgov.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Coburn</last_name>
      <phone>650-736-9551</phone>
      <email>cellsforSCI@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gary K Steinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen McKenna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shepherd Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Admissions</last_name>
      <phone>800-743-7437</phone>
      <email>admissions@shepherd.org</email>
    </contact>
    <investigator>
      <last_name>Donald P Leslie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulina Aguilar</last_name>
      <phone>312-942-7877</phone>
      <email>Paulina_Aguilar@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carol MacPherson</last_name>
      <email>Carol_L_MacPherson@rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard G Fessler, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Cero</last_name>
      <phone>317-396-1298</phone>
      <email>hcero@goodmancampbell.com</email>
    </contact>
    <investigator>
      <last_name>Eric M Horn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Evans</last_name>
      <phone>314-362-3473</phone>
      <email>evansj@wudosis.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Wilson Zack Ray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Klis</last_name>
      <phone>414-805-7183</phone>
      <email>cklis@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Kurpad Shekar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>November 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical spinal cord injury</keyword>
  <keyword>AST-OPC1</keyword>
  <keyword>SCiStar</keyword>
  <keyword>OPC1</keyword>
  <keyword>Neural cell</keyword>
  <keyword>Trauma spinal cord</keyword>
  <keyword>stemcell transplant</keyword>
  <keyword>Cervical spine injury</keyword>
  <keyword>Paralysis</keyword>
  <keyword>Quadriplegia</keyword>
  <keyword>Tetraplegia</keyword>
  <keyword>Spine injury</keyword>
  <keyword>oligodendrocyte progenitor cell</keyword>
  <keyword>Subacute spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Spinal Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
